New commercial boss for Notts pharma firm

Azhar Kalim

Quotient Clinical, the Ruddington-based drug development services provider, has appointed Azhar Kalim as chief commercial officer.

Kalim will lead the enhanced commercial team in a new role, with a focus on supporting Quotient’s strategy to further develop its global commercial footprint following two recent US acquisitions.

Quotient has recently bought SeaView Research, a specialist early phase clinical pharmacology business, and QS Pharma, a small molecule formulation development and manufacturing business.

Mark Egerton, chief executive officer, said: “Azhar has over 25 years’ experience in the drug development services sector, as a leader in expanding research capabilities and creating unique service offerings to the biopharma industry. Quotient takes pride in being a highly customer focused organisation and we are delighted to welcome Azhar in this vital role at an exciting point in the company’s development. I look forward to working with him on a continued journey of growth and success.”

Kalim said: “Quotient’s integrated capabilities offer a unique solution to our clients. I am delighted to be joining a dynamic and rapidly expanding business, and I look forward to working with the team to build long term, sustainable, and strategic relationships with our customers.”

Click here to sign up to receive our new South West business news...
Close